DCF Advisers’s Ionis Pharmaceuticals IONS Stock Holding History

DCF Advisers’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$4.21M	Sell	56,000 -47,000	-46%	-$3.71M	1.12%	23
2025 Q4	$8.15M	Sell	103,000 -5,413	-5%	-$408K	2.19%	8
2025 Q3	$7.09M	Buy	108,413 +16,663	+18%	+$814K	2.28%	9
2025 Q2	$3.63M	Sell	91,750 -3,250	-3%	-$106K	1.68%	21
2025 Q1	$2.87M	Buy	95,000 +12,118	+15%	+$397K	1.37%	25
2024 Q4	$2.9M	Buy	82,882 +43,382	+110%	+$1.62M	1.4%	24
2024 Q3	$1.58M	Buy	39,500 +16,500	+72%	+$768K	0.63%	36
2024 Q2	$1.1M	Buy	+23,000	New	+$943K	0.56%	44

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DCF Advisers's IONS Position: Q1 2026 in Review

DCF Advisers reduced its Ionis Pharmaceuticals (IONS) stake by 46% in Q1 2026, selling an estimated $3.71M and leaving 56,000 shares worth $4.21M. The position accounts for 1.12% of the portfolio, ranked #23.

DCF Advisers first reported a position in IONS in Q2 2024 and has held it in 8 quarters since. The position peaked at $8.15M in Q4 2025. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

DCF Advisers held 56,000 shares of Ionis Pharmaceuticals worth $4.21M as of Q1 2026.
DCF Advisers sold 47,000 Ionis Pharmaceuticals shares in Q1 2026, an estimated $3.71M.
Ionis Pharmaceuticals made up 1.12% of DCF Advisers's portfolio in Q1 2026, its #23 holding.
DCF Advisers first reported a position in Ionis Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
DCF Advisers's Ionis Pharmaceuticals position peaked at $8.15M in Q4 2025.
493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on DCF Advisers's 13F filing for Q1 2026, filed 11 May 2026.